21 Erie Street
Cambridge, MA 02139
United States
617 564 0013
https://primemedicine.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 234
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Keith Michael Gottesdiener M.D., Ph.D. | President, CEO, Secretary & Director | 1,06M | N/D | 1954 |
Dr. Ann L. Lee Ph.D. | Chief Technical Officer | 684,78k | N/D | 1962 |
Dr. Jeremy S. Duffield M.D., Ph.D. | Chief Scientific Officer | 680,65k | N/D | 1968 |
Dr. Andrew Anzalone M.D., Ph.D. | Co-Founder & Head of Prime Editing Platform | N/D | N/D | 1987 |
Dr. David R. Liu Ph.D. | Co-Founder & Chair of Scientific Advisory Board | N/D | N/D | N/D |
Dr. Allan Reine M.D. | Chief Financial Officer | N/D | N/D | 1975 |
Dr. Meredith Goldwasser | Senior VP and Head of Strategy & Corporate Operations | N/D | N/D | 1971 |
Ms. Carman Alenson CPA, M.B.A. | Senior VP of Finance & Chief Accounting Officer | N/D | N/D | 1966 |
Dr. Karen Brown J.D., Ph.D. | Senior Vice President of Intellectual Property & Legal Affairs | N/D | N/D | N/D |
Ms. Niamh Alix | Chief Human Resources Officer | N/D | N/D | N/D |
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.
L'ISS Governance QualityScore di Prime Medicine, Inc. al 1 giugno 2024 è 9. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 10; diritti degli azionisti: 8; retribuzione: 8.